28 Feb 2017
KINEDMD study: developing an activity monitoring biomarker Using novel algorithms to chart daily activities of ambulant and non-ambulant boys The ground-breaking KineDMD project is a collaborative effort between Imperial College London, UCL and Great Ormond Street...
31 Jan 2017
Blood-based biomarker Developing a more informative measure of disease progression and response to new treatments Although Duchenne has been studied for many years, classic measures of disease progression rely on basic observations of movement, such as the six-minute...
31 Jan 2017
Non-invasive imaging biomarker Reducing biopsies and improving dystrophin analysis Biopsies have become a difficult necessity for Duchenne patients who are involved in clinical trials. In addition to the stress on patients, each muscle can present disease differently,...
31 Jan 2017
LTBP4 Targeting muscle inflammation and fibrosis With the funds raised in 2016, the DRF is tackling inflammation and fibrosis, which are two key problems for Duchenne boys. It is believed that the protein LTBP4 prevents the activation of a key biological pathway...
18 Dec 2016
Vamorolone Alternative to existing steroids for all with Duchenne In January 2024, vamrolone became the first drug for all people with Duchenne muscular dystrophy to be approved in the US, the EU and the UK. In December 2024, it was approved by NICE for use on the...